Phillip Stoup advises companies, investment banks, and private equity firms in capital markets transactions particularly in the life sciences and technology sectors.

Mr. Stoup represents issuers, underwriters, and initial purchasers on a range of transactions, including:

  • Initial public offerings (IPOs)
  • Follow-on and secondary offerings
  • Registered and 144A convertible debt offerings
  • Private placements of public equity (PIPEs)
  • Acquisition financing
  • Strategic investments

He also advises companies on securities law compliance and general corporate governance matters.

Mr. Stoup draws on experience with robust deal flow — he has advised on billions of dollars' worth of financings — and a global perspective gained from six years resident in Latham’s London office.

Mr. Stoup has worked with the following companies, representing them in initial public offerings, venture financings, as well as advising them on legal and business matters:

  • 4D Molecular Therapeutics
  • CARGO Therapeutics
  • Cloudera
  • Coherus BioSciences
  • Corsair Gaming
  • Neumora Therapeutics
  • Nevro
  • Opendoor
  • Planet Labs
  • Postmates

He has represented the underwriters on IPOs and follow-on offerings for the following:

  • AveXis
  • Allogene
  • BridgeBio
  • Kronos Bio
  • MyoCardia
  • Silverback Therapeutics

Mr. Stoup also regularly advises investment banks, including the following, on offerings for life sciences and technologies companies:

  • BofA Merrill Lynch
  • Citigroup
  • Cowen and Company
  • Credit Suisse
  • Goldman Sachs
  • Jefferies
  • J.P. Morgan
  • Leerink Partners
  • Morgan Stanley
  • RBC Capital

Bar Qualification

  • California


  • JD, Duke University School of Law, 2009
    cum laude, Duke Law Journal
  • BA, University of California, Berkeley, 2005
    cum laude, Distinction in General Scholarship
  • BS, University of California, Berkeley, 2005
    cum laude